Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.39 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12945871 | 0.88 | ADAM17 (0.45) | ADAM17RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL20750037 | 0.76 | DDAH1 (0.51) | RAB9AMAPTALDH1A1TDP1POLB | |
| SCHEMBL24018628 | 0.71 | ADAM17 (0.67) | ADAM17MAPTALDH1A1 | |
| SCHEMBL20621743 | 0.70 | ADAM17 (0.61) | ADAM17 | |
| SCHEMBL19975822 | 0.69 | ADAM17 (0.56) | ADAM17MAPTALDH1A1L3MBTL1 | |
| SCHEMBL12945694 | 0.69 | ALDH1A1 (0.44) | MAPTALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL20796060 | 0.68 | ADAM17 (0.61) | ADAM17MAPTALDH1A1 | |
| SCHEMBL23351977 | 0.68 | ADAM17 (0.54) | ADAM17MAPTALDH1A1L3MBTL1 | |
| SCHEMBL1107141 | 0.67 | LMNA (0.73) | RAB9AALDH1A1SMN1; SMN2NPC1POLB | |
| SCHEMBL12945876 | 0.67 | ALDH1A1 (0.36) | ADAM17RAB9AALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2842575-A1 | Auristatin drug linker conjugates | Seattle Genetics, Inc. (US) | 2015-03-04 | — | — | EP | disclosed |
| EP-2265283-B1 | AURISTATIN DRUG LINKER CONJUGATES | SEATTLE GENETICS INC (US) | 2014-09-03 | — | — | EP | disclosed |
| US-20110020343-A1 | AURISTATIN DRUG LINKER CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020343-A1 | AURISTATIN DRUG LINKER CONJUGATES | AURKA, AURKC, AURKB | ADAM17 294/4885RAB9A 2870/4885MAPT 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.